What is Von Hippel-Lindau Disease

Von Hippel-Lindau (VHL) disease is a rare genetic disorder characterized by the abnormal growth of both benign and malignant tumors and cysts in multiple organ systems. It is caused by a mutation in the VHL gene, which normally functions to suppress tumor development, leading to a predisposition for various vascular and organ-specific growths throughout a patient's lifetime.

What causes Von Hippel-Lindau disease?

Von Hippel-Lindau disease is an autosomal dominant genetic condition, meaning an individual only needs to inherit one mutated copy of the VHL gene from a parent to develop the disease, though approximately 20% of cases arise from a spontaneous (de novo) mutation. The VHL gene is a tumor suppressor gene located on chromosome 3p25. When this gene is non-functional, the body cannot properly regulate a protein called hypoxia-inducible factor (HIF). The resulting accumulation of HIF triggers the overproduction of vascular endothelial growth factor (VEGF), which leads to the characteristic formation of highly vascularized tumors and cysts.

Which body systems are affected by Von Hippel-Lindau disease?

Because the VHL gene is expressed in many tissues, Von Hippel-Lindau disease can affect various systems. Clinical manifestations are diverse and often include the following:

• Central Nervous System: Hemangioblastomas (benign blood vessel tumors) frequently occur in the cerebellum, spinal cord, and retina.


• Kidneys: Patients are at high risk for renal cysts and clear cell renal cell carcinoma (kidney cancer).


• Adrenal Glands: Pheochromocytomas, which are tumors that can cause episodes of high blood pressure and palpitations.


• Pancreas: Development of pancreatic cysts or neuroendocrine tumors.


• Reproductive System: Cystadenomas of the epididymis (in males) or the broad ligament (in females).

How common is Von Hippel-Lindau disease and who is affected?

Von Hippel-Lindau disease is estimated to occur in approximately 1 in 36,000 to 1 in 53,000 live births. It affects males and females equally, and there is no known geographic or ethnic predilection. While the genetic mutation is present from birth, symptoms are rarely present at birth; they typically manifest in early adulthood, often between the ages of 20 and 40. However, the age of onset can vary significantly between family members, necessitating lifelong clinical surveillance.

How is Von Hippel-Lindau disease classified?

Clinicians often classify Von Hippel-Lindau disease based on the specific clinical manifestations observed in a patient. Type 1 VHL is generally characterized by a low risk of pheochromocytoma, whereas Type 2 is subdivided into Type 2A, 2B, and 2C based on the specific risk and presence of pheochromocytoma, renal cell carcinoma, and pancreatic tumors. Understanding these classifications helps medical teams tailor the frequency and type of screening required for each individual.

Next steps

• Consult a genetic counselor to discuss family screening and the implications of VHL gene testing.


• Establish care with a multidisciplinary medical team, including urologists, neurologists, and endocrinologists familiar with Von Hippel-Lindau disease.


• Join the DiseaseMaps.org community to connect with over 100 other members navigating life with this condition.


• Maintain a rigorous, lifelong surveillance schedule as recommended by the NIH or VHL-specific clinical guidelines.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with your physician regarding your specific health needs.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Von Hippel-Lindau disease overview.


• Orphanet: Rare disease database for Von Hippel-Lindau syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #193300 (Von Hippel-Lindau Syndrome).


• VHL Alliance: Patient resources and clinical research updates.